valor de las acciones
Competidores
| Simbolo bursátil | Precio | Pronóstico 1A | Pronóstico 2A | Cap. Mercado | Div Yld | Tasa de crecimiento |
|---|---|---|---|---|---|---|
|
NYSE:LLY
Eli Lilly and
|
775.00 | -49.06% | -28.16% | 697,814.17 | 0.67% | 2.63% |
|
NYSE:MRK
Merck
|
129.55 | -8.88% | 4.48% | 328,125.06 | 2.36% | -19.03% |
|
NYSE:ABBV
AbbVie
|
160.45 | -20.2% | -9.65% | 283,333.49 | 3.81% | 7.03% |
|
LSE:AZN
AstraZeneca PLC
|
122.64 | 17.42% | 39.84% | 190,120.82 | 2.04% | 15.98% |
|
SWX:ROG
Roche Holding
|
222.30 | 33.69% | 50% | 179,414.05 | 4.34% | 0.43% |
|
NYSE:PFE
Pfizer
|
28.27 | 9.82% | 40.42% | 160,080.04 | 6.05% | -9.31% |
|
NasdaqGS:REGN
Regeneron Pharmaceuticals
|
955.76 | -27.64% | -21.47% | 105,310.9 | 0% | 13.9% |
|
NYSE:BMY
Bristol-Myers Squibb
|
43.67 | 63.07% | 73.49% | 88,523.46 | 5.45% | 13.54% |
|
SHSE:600276
Jiangsu Hengrui Medicine
|
46.42 | 35.37% | 72.24% | 295,164.35 | 0.42% | 1.61% |
|
SEHK:1093
CSPC Pharmaceutical Group
|
6.65 | 34.36% | 50.64% | 78,766.8 | 4.2% | 19.3% |
|
SEHK:1801
Innovent Biologics
|
40.00 | 0% | 0% | 64,907.32 | 0% | 0% |
|
SHSE:600196
Shanghai Fosun Pharmaceutical (Group)
|
24.17 | 91.44% | 183.66% | 57,741.51 | 1.12% | -2.01% |
|
SEHK:9926
Akeso
|
50.25 | 0% | 0% | 43,509.32 | 0% | -,262.86% |
|
SZSE:300003
Lepu Medical Technology (Beijing)
|
14.85 | 185.62% | 251.51% | 27,400.16 | 2.22% | 0.34% |
|
SEHK:1877
Shanghai Junshi Biosciences
|
12.78 | 0% | 0% | 27,513.36 | 0% | 0% |
|
SHSE:600062
China Resources Double-Crane Pharmaceutical
|
22.88 | 0% | 0% | 22,226.69 | 1.11% | 13.43% |
|
NasdaqGM:ZLAB
Zai Lab
|
16.57 | 0% | 0% | 1,635.75 | 0% | 0% |
|
SEHK:9969
InnoCare Pharma
|
5.01 | 0% | 0% | 9,404.27 | 0% | 0% |
|
SEHK:2696
Shanghai Henlius Biotech
|
17.48 | 0% | 0% | 8,869.84 | 0% | -,171.88% |
|
SEHK:9966
Alphamab Oncology
|
4.98 | 0% | 0% | 4,583.01 | 0% | 0% |
